OncoMed shares crushed as Celgene-partnered lead drug flops and Bayer takes a pass on options
It’s a black day at OncoMed $OMED. A little more than a year after its number two drug foundered in a Phase II failure, its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
